Key result
New lung and colorectal cancer diagnoses linked to ~3-point greater drops in cardiometabolic medication adherence.
Why the study?
A cancer diagnosis can influence adherence to chronic condition medications, but changes in adherence by cancer type and condition are not well described.
Does a new diagnosis of non-metastatic breast, colorectal, lung, or prostate cancer alter adherence to chronic medications for diabetes, hyperlipidemia, and hypertension compared with matched cancer-free individuals in older Medicare beneficiaries?
Cohort (n=34,395)
Yes
Does a new diagnosis of non-metastatic breast, colorectal, lung, or prostate cancer alter adherence to chronic medications for diabetes, hyperlipidemia, and hypertension compared with matched cancer-free individuals in older Medicare beneficiaries?
Older adults diagnosed with colorectal or lung cancer experience modest but significant declines in adherence to statins and oral anti-diabetic medications compared to cancer-free peers, highlighting a need for coordinated cardiometabolic care during cancer survivorship.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Cancer history, treatment-related toxicity and metabolic derangements, ASCVD risk factors, competing mortality, prognosis, and drug interactions must be incorporated into lipid-management decisions rather than treated as secondary considerations.”
May warrant closer cardiometabolic monitoring after colorectal or lung cancer diagnosis in older adults; extends prior breast cancer observations but remains hypothesis-generating.
Objectives A cancer diagnosis can influence medication adherence for chronic conditions by shifting care priorities or reinforcing disease prevention. This study describes changes in adherence to medications for treating three common chronic conditions – diabetes, hyperlipidemia, and hypertension – among older adults newly diagnosed with non-metastatic breast, colorectal, lung, or prostate cancer. Methods We identified Medicare beneficiaries aged ≥66 years newly diagnosed with cancer and using medication for at least one chronic condition, and similar cohorts of matched individuals without cancer. To assess medication adherence, proportion of days covered (PDC) was measured in six-month windows starting six-months before through 24 months following cancer diagnosis or matched index date. Generalized estimating equations were used to estimate difference-in-differences (DID) comparing changes in PDCs across cohorts using the pre-diagnosis window as the referent. Analyses were run separately for each cancer type-chronic condition combination. Results Across cancer types and non-cancer cohorts, adherence was highest for anti-hypertensives (90–92%) and lowest for statins (77–79%). In older adults with colorectal and lung cancer, adherence to anti-diabetics and statins declined post-diagnosis compared with the matched non-cancer cohorts, with estimates ranging from a DID of −2 to −4%. In older adults with breast and prostate cancer cohorts, changes in adherence for all medications were similar to non-cancer cohorts. Conclusion Our findings highlight variation in medication adherence by cancer type and chronic condition. As many older adults with early stage cancer eventually die from non-cancer causes, it is imperative that cancer survivorship interventions emphasize medication adherence for other chronic conditions.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Lund et al. (2020) conducted a cohort in Older adults with non-metastatic breast, colorectal, lung, or prostate cancer and chronic cardiometabolic conditions (diabetes, hyperlipidemia, or hypertension) (n=34,395). Incident diagnosis of stage I-III breast, colorectal, non-small cell lung, or prostate cancer vs. Exact-matched Medicare beneficiaries without a history of cancer (matched up to 1:5 on age, sex, race, and SEER region) was evaluated on Difference-in-differences (DID) in medication adherence measured by mean proportion of days covered (PDC) for anti-hypertensives, non-insulin anti-diabetics, and statins in 6-month windows through 24 months post-diagnosis compared with the 6-month pre-diagnosis window (MD -1.88% (lung cancer anti-hypertensive PDC in survivorship phase); DID range -1.94% to -4.46% for anti-diabetics and -1.35% to -3.44% for statins in lung and colorectal cancer, 95% CI -3.13% to -0.64%). Colorectal and lung cancer diagnoses were associated with 2% to 4% larger declines in statin and anti-diabetic adherence compared with matched cancer-free cohorts over 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: